Company: INKT
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-061041
Chunk: 32

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 32
---
 Lexington, Massachusetts 02421. (2) Based on Schedule 13G filed by GKCC with the SEC on May 22, 2024. The principal business address of the beneficial owner is 501 Silverside Road, Suite 87AVA, Wilmington, DE 19809.

<div align='center'>23

DELINQUENT SECTION 16(a) REPORTS</div>

Our executive officers, directors, and 10% stockholders are required under Section 16(a) of the 1934 Act, to file reports of ownership and changes in ownership of our securities with the SEC.

Based solely on a review of the copies of reports furnished to us, we believe that during our 2024 fiscal year, all Section 16(a) filing requirements were timely filed other than the reports of ownership and changes in ownership filed related to Dr. Kadlec's Board appointment.

### CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Certain Relationships

Garo H. Armen, Ph.D. (Chairman of the Board), Brian Corvese (Director), and Christine Klaskin (Treasurer) are all officers and/or directors of Agenus. Jennifer S. Buell, Ph.D., is a director and officer of Agenus in the role of Chairman of the Agenus Executive Counsel. These individuals, as well as Marc van Dijk, Ph.D.(former Chief Scientific Officer of MiNK), own Agenus equity and Agenus equity awards. Their relationship with Agenus and/or the ownership of any Agenus equity or equity awards creates, or may create the appearance of, conflicts of interest when we ask these individuals to make decisions that could have different implications for Agenus than the decisions have for us. Under these provisions, neither Agenus or its other affiliates, nor any of their officers, directors, agents or stockholders, will have any obligation to present to us certain corporate opportunities. For example, a director of our company who also serves as a director, officer or employee of Agenus or any of its other affiliates may present to Agenus certain acquisitions, in-licenses, potential development programs or other opportunities that may be complementary to our business and, as a result, such opportunities may not be available to us. To the extent attractive corporate opportunities are allocated to Agenus or its other affiliates instead of to us, we may not be able to benefit from these opportunities. Additionally, conflicts of interest and certain other disputes may arise between